CCCC
NASDAQC4 Therapeutics Inc.
News · 26 weeks38+500%
2026-04-192026-10-11
Mix1490d
- Other6(43%)
- SEC Filings4(29%)
- Insider3(21%)
- Analyst1(7%)
Latest news
25 items- ANALYSTAnalyst initiated coverage on C4 Therapeutics with a new price targetAnalyst initiated coverage of C4 Therapeutics with a rating of Overweight and set a new price target of $10.00
- INSIDERDirector Anderson Kenneth Carl was granted 3,662 shares, increasing direct ownership by 5% to 75,612 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERDirector Grogan Donna Roy was granted 4,618 shares, increasing direct ownership by 6% to 79,471 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual MeetingImmunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elranatamab Reinforce Cemsidomide’s Ability to Drive T-cell Expansion and Activation, and Prevent T-cell Exhaustion When Combined with Immune-based Therapies First Cemsidomide Dose Level (75 µg) in Phase 1b Trial with Elranatamab Declared Safe by Safety Data Review Committee; Advancing Trial to Dose Expansion and Escalation Cohorts with Data from All Cohorts Evaluated Expected in Mid-2027 WATERTOWN, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -
- INSIDERChief Financial Officer Adams Kendra converted options into 6,250 shares and covered exercise/tax liability with 2,775 shares, increasing direct ownership by 0.92% to 382,323 units (SEC Form 4) (for withholding tax)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- PRC4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual MeetingWATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting. The data characterize the immune effects on T cells and natural killer (NK) cells across the once-daily dose levels evaluated in the Phase 1 trial, further supporting cemsidomide’s potential as a combination partner for immune-based thera
- SECSEC Form 144 filed by C4 Therapeutics Inc.144 - C4 Therapeutics, Inc. (0001662579) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
- SECSEC Form 10-Q filed by C4 Therapeutics Inc.10-Q - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsCemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Presented at European Hematology Association (EHA) 2026 Congress Further Support Cemsidomide’s Potential Best-in-Class Profile in Multiple Myeloma Phase 1b Trial of Cemsidomide in Combination With Approved Standard of Care Multiple Myeloma Therapies On Track to Initiate in 1H 2027 WATERTOWN, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the
- PRC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 162,880 shares of the Company’s common stock to one new employee (the "Inducement Grant"), with the grant made on August 10, 2026 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listi
- INSIDERChief Medical Officer Reyno Leonard converted options into 15,325 shares and covered exercise/tax liability with 7,397 shares, increasing direct ownership by 2% to 372,406 units (SEC Form 4) (for tax liability)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERDirector Grogan Donna Roy was granted 3,341 shares, increasing direct ownership by 5% to 74,853 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERDirector Anderson Kenneth Carl was granted 2,650 shares, increasing direct ownership by 4% to 71,950 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Hughes Owen4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoerter Steven L.4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Koppikar Utpal4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Anderson Kenneth Carl4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Cooper Ronald Harold Wilfred4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Bessen Laura4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Fawell Stephen4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Director Grogan Donna Roy4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
CCCC FAQ
7 questionsWhat does C4 Therapeutics Inc. do?
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors...Where does CCCC stock trade?
C4 Therapeutics Inc. (CCCC) is listed on NASDAQ.What sector and industry is CCCC in?
C4 Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did C4 Therapeutics Inc. go public?
C4 Therapeutics Inc. (CCCC) completed its IPO in 2020.What are analysts saying about CCCC?
C4 Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $1000.00 price target on 2026-10-09. Recent price targets range from $400.00 to $1200.00.What companies are similar to CCCC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CCCC side-by-side with any of them on Quantisnow.How can I track CCCC on Quantisnow?
Quantisnow aggregates C4 Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CCCC to receive live email and push alerts on every new disclosure.